Fighting Systemic Inflammatory Disease

Wednesday September 25, 2019

Therapies that target and treat systemic inflammatory disease are important tools in the fight against conditions such as psoriasis and rheumatoid disease. However, traditional therapies are limited in reach and may cause severe side effects that can often lead to a lower quality of life, such as infections, cancer and death. Unfortunately, many current medications and treatment options only focus on symptoms of these diseases and fail to treat the underlying cause of the condition. This practice puts patients at risk, can lead to a poor quality of life or even death.  Abcentra, with our innovative approach to treatment, is looking to change this approach.

Inflammation is a primary driver behind many fatal and life-threatening diseases. However, many traditional treatment options do not focus on addressing inflammation. Research shows that oxidized low-density lipoprotein (oxLDL) is implicated in these chronic, common conditions caused by inflammation. Traditional therapies fail to target oxLDL and fail to treat underlying inflammation found in systemic inflammatory disease such as accelerated atherosclerosis, psoriasis and rheumatoid disease. Creating safer, better options is critical for patients living with these conditions to have a fuller life.

Abcentra’s leading candidate, orticumab, is being developed to treat atherosclerosis, as well as psoriasis in patients with rheumatic disease. It is the only fully-human monoclonal antibody of its kind. Orticumab addresses these unmet needs in inflammation by specifically targeting oxLDL. This means that by using orticumab, patients are using therapies that treat the underlying cause of their disease, with fewer dangerous side effects. In addition, orticumab is able to reach a greater population without severe side effects and provide treatment options where no treatments exist.

By targeting more specific mechanisms of inflammation with more biological specificity, we can reach a greater therapeutic population without the side effects and safety concerns associated with systemic immunological targets and give patients a better quality of life.

Read more about our lead candidate here, then view our pipeline to learn more about the other treatment options currently in development.